CPEB4 Inhibit Cell Proliferation via Upregulating p21 mRNA Stability in Renal Cell Carcinoma

Jiehui Di, Hui Wang, Zhongjun Zhao, Guang Zhao, Xiaobing Qin, Zhengxiang Han, Yong LiuFrontiers in Cell and Developmental Biology 2021 · DOI

TL;DR

This study reveals that CPEB4 acts as a tumor suppressor in Renal Cell Carcinoma (RCC) by downregulating its expression. It inhibits tumor growth by stabilizing p21 mRNA, leading to G1 cell cycle arrest. This discovery positions CPEB4 as a potential prognostic biomarker for RCC patients.

What Problem Does This Paper Address?

Renal Cell Carcinoma (RCC) remains a significant cause of cancer-related mortality, and while treatments have improved, many patients still experience disease progression. Understanding the molecular mechanisms driving RCC development is crucial for identifying new therapeutic targets and biomarkers. Cytoplasmic polyadenylation element-binding protein 4 (CPEB4) is a RNA-binding protein known to be dysregulated in various cancers, but its specific role in RCC was unclear. Previous research has shown CPEB4 can act as either an oncogene or a tumor suppressor depending on the cancer type, highlighting the need to clarify its function in RCC. This paper aims to elucidate the role of CPEB4 in RCC and its underlying molecular mechanisms, particularly its impact on cell proliferation and the cell cycle.

Methods

The researchers employed a multi-faceted approach to investigate CPEB4's role in RCC:

  • Clinical Specimen Analysis: Western blotting and RT-qPCR were used to assess CPEB4 protein and mRNA levels in RCC tissues and matched normal samples, as well as in various RCC cell lines and a normal renal tubular epithelial cell line.
  • TCGA Database Analysis: Publicly available data from The Cancer Genome Atlas (TCGA) was analyzed to correlate CPEB4 expression with patient survival outcomes (overall and disease-free survival).
  • In Vitro Studies:
    • Cell Proliferation Assays: CCK-8 and colony formation assays were performed to measure the impact of CPEB4 knockdown (using siRNA) and overexpression on RCC cell growth and colony-forming ability.
  • Cell Cycle Analysis: Flow cytometry was used to analyze the cell cycle distribution (G1, S, G2/M phases) after manipulating CPEB4 levels.
  • mRNA Stability Assays: Actinomycin D was used to inhibit de novo mRNA synthesis, allowing researchers to assess the effect of CPEB4 on p21 mRNA stability.
  • RNA Immunoprecipitation (RIP): This technique was used to determine if CPEB4 directly binds to the p21 transcript.
  • Immunofluorescence Staining: Used to visualize the cellular localization of CPEB4.
  • In Vivo Studies:
    • Xenograft Assays: Nude mice were injected with ACHN cells (with CPEB4 knockdown) or 7860 cells (with CPEB4 overexpression) to assess the effect of CPEB4 on tumor growth, volume, and weight.

Datasets

  • Clinical RCC Specimens: 15 pairs of RCC tissues and matched adjacent normal tumor samples were collected from the Affiliated Hospital of Xuzhou Medical University.
  • RCC Cell Lines: Four human RCC cell lines (ACHN, OSRC2, 786O, and Ketr-3) and one normal renal tubular epithelial cell line (HK2) were used.
  • TCGA Database: Publicly available data for Renal Cell Carcinoma (KIRC and KIRP) was utilized for survival analysis.

Key Insights and Ideas

  • CPEB4 as a Tumor Suppressor in RCC: The consistent downregulation of CPEB4 in RCC tissues and cell lines, coupled with its correlation with poorer patient survival, strongly suggests a tumor-suppressive role for CPEB4 in this cancer. This contrasts with its oncogenic role in some other cancers, highlighting the context-dependent nature of CPEB4's function.
  • Mechanism of p21 Regulation: The study uncovers a novel mechanism where CPEB4 directly binds to the 3'-UTR of p21 mRNA, stabilizing it and thereby increasing p21 protein levels. This is a significant finding as p21 is a well-known cell cycle inhibitor and tumor suppressor.
  • CPEB4's Role Upstream of p21: The research positions CPEB4 as acting upstream of p21, influencing its expression through mRNA stability. This provides a clear molecular link between CPEB4 and a key cell cycle regulator.
  • CPEB4's Impact on Cell Cycle Progression: By upregulating p21, CPEB4 effectively induces G1 cell cycle arrest, which in turn inhibits cell proliferation and tumor growth. This provides a direct mechanistic explanation for CPEB4's anti-tumor effects.

Key Results

  • Downregulated CPEB4 in RCC: CPEB4 protein and mRNA levels were significantly lower in RCC tissues and cell lines compared to normal counterparts.
  • Prognostic Significance: Low CPEB4 expression was significantly associated with shorter overall survival and disease-free survival in RCC patients.
  • Inhibition of Tumor Growth: Knockdown of CPEB4 promoted RCC cell proliferation and colony formation in vitro, while overexpression suppressed it. In vivo, CPEB4 knockdown led to larger tumors, whereas overexpression inhibited tumor growth.
  • G1 Cell Cycle Arrest: CPEB4 overexpression induced G1 cell cycle arrest, while its knockdown promoted G1/S phase transition.
  • p21 Upregulation: CPEB4 overexpression led to increased p21 protein and mRNA levels, and this effect was mediated by increased p21 mRNA stability.
  • CPEB4-p21 Interaction: RNA immunoprecipitation confirmed that CPEB4 directly binds to the p21 transcript.
  • p21 Dependence: Restoring p21 expression in CPEB4-knockdown cells abrogated the pro-proliferative effect of CPEB4 knockdown, and silencing p21 in CPEB4-overexpressing cells reversed the cell cycle arrest, demonstrating that p21 is a key mediator of CPEB4's tumor-suppressive function.

Limitations and Future Work

  • Isoform Specificity: The study utilized the longest isoform of CPEB4 (CPEB4A). The authors acknowledge that CPEB4 has five isoforms (A-E) and suggest that alternative splicing of CPEB4 might contribute to its contradictory roles in different cancers, warranting further investigation.
  • p53 Interaction: While previous studies suggest a link between CPEB family members and p53, this study found that CPEB4 manipulation did not affect p53 expression but significantly upregulated p21. Further research is needed to explore the complex interactions within the CPEB family and their regulation of the p53 pathway.
  • Mechanisms of CPEB4-p21 Interaction: Although the study demonstrates CPEB4's role in stabilizing p21 mRNA, the precise molecular mechanisms of this interaction and the downstream effects of p21 in CPEB4-mediated growth inhibition could be further explored.
  • Therapeutic Potential: The findings suggest CPEB4 as a promising predictive biomarker for RCC prognosis. Future work could explore therapeutic strategies that target CPEB4 or its downstream effectors for RCC treatment.

Summary updated

Abstract

Cytoplasmic polyadenylation element-binding protein 4 (CPEB4) has been reported to be dysregulated in a variety of cancers and seems to play paradoxical roles in different cancers. However, the functional roles of CPEB4 in Renal cell carcinoma (RCC) are still unclear. This study aims to explore the role and underlying mechanism of CPEB4 in RCC. We found that the relative expression level of CPEB4 is down-regulated in RCC tissues and cell lines, and the low CPEB4 expression is correlated with short overall and disease-free survival of RCC patients. CPEB4 significantly inhibits RCC tumor growth both <i>in vivo</i> and <i>in vitro</i>. CPEB4 exerts an anti-tumor effect by increasing p21 mRNA stability and inducing G1 cell cycle arrest in RCC. Our data revealed that CPEB4 is a tumor suppressor gene that restrains cell cycle progression upstream of p21 in RCC. These findings revealed that CPEB4 may become a promising predictive biomarker for prognosis in patients with RCC.
BibTeX
@inproceedings{di2021cpeb,
  author = {Jiehui Di and Hui Wang and Zhongjun Zhao and Guang Zhao and Xiaobing Qin and Zhengxiang Han and Yong Liu},
  title = {{CPEB4 Inhibit Cell Proliferation via Upregulating p21 mRNA Stability in Renal Cell Carcinoma}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2021},
  doi = {10.3389/fcell.2021.687253},
}
Figure